Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

489 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Does engagement matter? The impact of patient and community engagement on implementation of cardiovascular health materials in primary care settings.
Zittleman L, Westfall JM, Callen D, Herrick AM, Nkouaga C, Simpson M, Dickinson LM, Fernald D, Kaufman A, English AF, Dickinson WP, Nease DE Jr. Zittleman L, et al. Among authors: herrick am. BMC Prim Care. 2024 Apr 25;25(1):135. doi: 10.1186/s12875-024-02365-w. BMC Prim Care. 2024. PMID: 38664665 Free PMC article. Clinical Trial.
Patients' perspectives on systemic sclerosis-related Raynaud's phenomenon in the feet: A qualitative study from the OMERACT Foot and Ankle Working Group.
Chapman LS, Alcacer-Pitarch B, Pauling JD, Flurey CA, Redmond AC, Richards P, Herrick AL, Merkel PA, Proudman S, Menz HB, Helliwell PS, Hannan MT, Domsic RT, Saketkoo LA, Shea B, Siddle HJ. Chapman LS, et al. Among authors: herrick al. Semin Arthritis Rheum. 2024 Apr;65:152372. doi: 10.1016/j.semarthrit.2024.152372. Epub 2024 Feb 2. Semin Arthritis Rheum. 2024. PMID: 38325052 Free article.
A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud's.
Tornling G, Edenius C, Pauling JD, Denton CP, Olsson A, Kowalski J, Murray A, Anderson M, Bhat S, Del Galdo F, Hall F, Korkosz M, Krasowska D, Olas J, Smith V, van Laar JM, Vonk MC, Wojteczek A, Herrick AL. Tornling G, et al. Among authors: herrick al. Rheumatology (Oxford). 2024 Jan 30:keae049. doi: 10.1093/rheumatology/keae049. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 38291895
Raynaud phenomenon: from GWAS to drug repurposing.
Herrick AL, Orozco G. Herrick AL, et al. Nat Rev Rheumatol. 2024 Mar;20(3):139-140. doi: 10.1038/s41584-024-01076-x. Nat Rev Rheumatol. 2024. PMID: 38228855 No abstract available.
Clinical trajectories of hand function impairment in systemic sclerosis: an unmet clinical need across disease subsets.
De Lorenzis E, Kakkar V, Di Donato S, Wilson M, Barnes T, Denton C, Derrett-Smith E, Douglas K, Helliwell P, Herrick AL, Saleem B, Nisar M, Morley C, Green L, Alcacer-Pitarch B, Del Galdo F. De Lorenzis E, et al. Among authors: herrick al. RMD Open. 2024 Jan 12;10(1):e003216. doi: 10.1136/rmdopen-2023-003216. RMD Open. 2024. PMID: 38216288 Free PMC article.
489 results